Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF TX-004HR IN POSTMENOPAUSAL WOMEN WITH MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY

Intervention/treatment:
TX-004HR (ESTRADIOL)
Medical condition:
VULVOVAGINAL ATROPHY
Protocol code:
TXV14-01
Control number:
180120
Status:
Closed
Approved:
December 22, 2014
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02253173
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: FEMALE
Age
40 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Sebastian Mirkin, MD, Chief Medical Officer
Organization
TherapeuticsMD
Phone:
561-961-1900
Extension 1952
Sponsor
THERAPEUTICSMD, INC

Locations

Quebec

Center for Research Saint-Louis
Québec, Quebec, G1W4R4
Clinique RSF Inc.
Québec, Quebec, G1S 2L6
Diex Research Montreal Inc.
Montreal, Quebec, H4N 3C5
Diex Research Sherbrooke Inc.
Sherbrooke, Quebec, J1H 1Z1
Manna Research Inc
Saint Romuald, Quebec, G6W 5M6

Results

See the results from the trial NCT02253173. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?